Novel TLR2-binding adjuvant induces enhanced T cell responses and tumor eradication

Author(s):
Zom, G.G.; Willems, M.M.J.H.P.; Khan, S.; Sluis, T.C. van der; Kleinovink, J.W.; Camps, M.G.M.; Marel, G.A. van der; Filippov, D.V.; Melief, C.J.M.; Ossendorp, F.
Published
2018
Publication type
Article / Letter to editor
Toll-like receptor 2AdjuvantCancer vaccinePeptide vaccinationT cell activation
Date issued
2018-12-12
Language
English
Is part of
Journal for ImmunoTherapy of Cancer
hdl
1887/78110
doi
10.1186/s40425-018-0455-2